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Pancreatic cancer is characterized by constitutive activation of the mitogen-activated pro-
tein kinase (MAPK) pathway. Mutations of KRAS or BRAF and epigenetic abrogation of
DUSP6 contribute synergistically to the constitutive activation of MAPK. Active MAPK
induces the expression of a variety of genes that are thought to play roles in malignant
phenotypes of pancreatic cancer. By blocking the functions of such induced genes, it is
possible to attenuate the malignant phenotypes.The development of drugs targeting genes
downstream of MAPK may provide a novel therapeutic option for pancreatic cancer.
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INTRODUCTION
Pancreatic cancer is one of the leading causes of cancer mortality
in Japan and many western countries (1, 2). Despite improvements
in diagnostic and therapeutic modalities, the 5-year survival rate
of patients with pancreatic cancer is still <10% (3). This poor
prognosis elicits a pressing need for the development of effective
diagnostic and therapeutic measures to improve patient survival.
An understanding of the molecular pathobiology involved may
provide clues that ultimately lead to the fulfillment of such needs.
Pancreatic cancer is characterized by constitutive activation of the
mitogen-activated protein kinase (MAPK) pathway. The purpose
of this review is to explore the mechanisms and relevance of MAPK
activation in the pathobiology of pancreatic cancer.
RAS–MAPK PATHWAY
The vast majority of pancreatic cancers involve gain-of-function
mutations in KRAS (4). KRAS encodes RAS, a guanosine triphos-
phate (GTP)-binding protein that, when activated by binding
with GTP, triggers stimulation of various downstream signaling
pathways (5). The activation of RAS is mediated by a guanine
nucleotide exchange factor, which is activated by upstream ligand-
binding receptor tyrosine kinases (5). Active RAS is self-inactivated
by intrinsic GTPase activity, with the help of a GTPase-activating
protein (5). Mutations of KRAS observed in pancreatic cancers
often occur in codons 12, 13, and 61, at most are G12D or
G12R substitutions, which attenuates the intrinsic GTPase activ-
ity, thus, such mutations result in prolonged activation of RAS
(6). Moreover, some pancreatic cancers harbor activating muta-
tions of BRAF rather than KRAS (7). BRAF encodes B-RAF, a
serine/threonine kinase belonging to a family of mitogen-activated
protein kinase kinase kinases (MAP3Ks). Mutations inBRAF com-
monly involve codon 600 and often result in a V600E substitution,
which leads to constitutive activation of its kinase function (8).
Mutations of KRAS and BRAF are mutually exclusive in pan-
creatic cancers, which suggest that the activating mutations of
these genes can compensate for each other in pancreatic cancer
phenotypes (7). B-RAF is an immediately downstream of RAS and
activates MAP2K1/MEK, which in turn activates MAPK1/ERK2.
Thus, the activating signal is passed on by a chain of kinase reac-
tions, which forms MAPK signaling pathway. Hence, activating
mutations of KRAS and BRAF ultimately result in activation of
the MAPK signaling pathway, which is crucial for pancreatic can-
cer (Figure 1). MAPKs are classified into three classes according to
their distinctive effectors, ERKs, JNKs, and p38MAPKs (9). Each
class of MAPK is involved in different functions, i.e., ERKs are
involved mainly in mitosis and proliferation, JNKs in apoptosis
and differentiation, and p38MAPKs in stress responses. Activated
MAPKs translocate into the nucleus and phosphorylate a variety
of transcription factors, altering the expression of various genes,
and therefore enacting specific cellular responses (10).
DUAL-SPECIFICITY PROTEIN PHOSPHATASES
Dual-specificity protein phosphatases dephosphorylate phospho-
rylated serine, threonine, or tyrosine residues of substrates. Dual-
specificity protein phosphatases (DUSPs) share a common struc-
ture that comprises a carboxyl-terminal catalytic domain and
an amino-terminal non-catalytic domain. The catalytic domain
contains a sequence homologous to the prototypic VH-1 DUSP
encoded by the vaccinia virus (11, 12). The non-catalytic domain
contains both a conserved cluster of basic amino acid residues
involved in specific recognition of MAPKs, known as the kinase
interaction motif, and sequences that determine the subcellular
localization of these enzymes (12, 13). MAPKs are prime sub-
strates for DUSPs, i.e., DUSPs primarily dephosphorylate target
residues in MAPKs and induce their inactivation. DUSPs are classi-
fied into three classes by their subcellular localization and substrate
specificities (12). The first class includes DUSP1, DUSP2, DUSP4,
and DUSP5, which act in the nucleus and have broad specifici-
ties toward various MAPKs. The second class includes DUSP6,
DUSP7, and DUSP9, which act in the cytoplasm and strictly on
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FIGURE 1 | Pancreatic cancer produces constitutively active MAPK.
Panels show histological images of invasive ductal adenocarcinoma (A) and
its expression of phosphorylated MAPK (B). Staining with hematoxylin and
eosin (A) and indirect immunohistochemistry using anti-phosphorylated
MAPK antibody (137F5, 1:250; Cell Signaling Technology Inc., Danvers, MA,
USA) and a Histofine SAB-PO kit (Nichirei Corp., Tokyo, Japan) according to
the manufacturer’s instructions (B). Original magnification was ×200.
MAPK1/ERK2 (13). The last class includes DUSP8, DUSP10, and
DUSP16, which act mainly on MAPK8/JNK1 and MAPK14/p38.
DUSPs and MAPKs form feedback loops, each controlling the
activities of the other.
DUSP6 IN PANCREATIC CANCER
Owing to its uniquely strict specificity toward MAPK1/ERK2
whose activation is involved in oncogenesis, an association
between DUSP6 and cancer has been a prime focus of study.
DUSP6 resides on the chromosome locus 12q21–22, which is com-
monly deleted in pancreatic cancer (14). In studies of genetic and
epigenetic alterations of DUSP6 in pancreatic cancer, mutations of
this gene have not been observed, however, marked reduction of its
expression has been found (15). This reduced expression is associ-
ated with constitutive activation of MAPK1/ERK2 and, despite the
presence of mutated KRAS, exogenous overexpression of DUSP6
induces dephosphorylation of MAPK1/ERK2, subsequent sup-
pression of proliferation, and eventual apoptosis of pancreatic
cancer cells (16). This indicates that, for their proliferation and
survival, pancreatic cancer cells are largely dependent on the acti-
vation of MAPK induced as a consequence of the synergistic effect
of mutations in KRAS and an abrogation of DUSP6.
While the expression of DUSP6 is markedly reduced in pan-
creatic cancer cells, the expression of DUSP6 can be restored
by treatment with 5-azacytidine, an inhibitor of DNA methyl-
transferase, which indicates that the reduced expression stems
from hypermethylation. A search for possible genomic regions of
hypermethylation pertaining to the reduced expression of DUSP6
resulted in the discovery of a cluster of methylated CpG in intron
1 of DUSP6 gene (17). A promoter assay indeed showed pro-
moter activity of the intron 1 (18). Moreover, this activity is
shown to be positively associated with activity of MAPK1/ERK2.
In other words, active MAPK1/ERK2 induces upregulation of the
promoter activity of DUSP6, resulting in an increase in its expres-
sion. The increased expression of DUSP6 leads to inactivation of
MAPK1/ERK2, hence, which indicates that a negative feedback
loop is formed between these two molecules (18).
Pancreatic cancer is hypothesized to develop through multistep
progression of dysplastic grades of epithelial cells in the pancreatic
duct along with accumulation of genetic abnormalities, which is
known as the progression model of pancreatic cancer (19). In this
progression model, low-grade dysplasia, termed low-grade pan-
creatic intraepithelial neoplasia (PanIN), is thought to progress
into high-grade dysplasia, or high-grade PanIN, and eventually
into invasive carcinoma. The progression is associated with an
accumulation of genetic aberrations in KRAS, CDKN2A, SMAD4,
and TP53 (19, 20). Therefore, PanIN is regarded as a precursor
lesion for pancreatic cancer. The expression of DUSP6 is increased
in PanINs while it is decreased in invasive carcinoma, which indi-
cates that DUSP6 may be a gatekeeper preventing progression of
the precursor lesion into a fully invasive cancer (21).
DUSP6 is also known to acquire post-translational control of
its expression. DUSP6 is degraded by the ubiquitin–proteasome
system. For such degradation to take place, serines 159 and 197
of DUSP6 need to be phosphorylated by MAPK1/ERK2 (22).
This phosphorylation event is regarded as a positive feedback
mechanism for the activation of MAPK1/ERK2 (22). The reduced
expression of DUSP6 in cancer cells might be due to the accel-
eration of this degradation system, which is indeed the case in
ovarian cancer cells. The accelerated degradation of DUSP6 in
these cells is associated with reactive oxygen species, therefore,
blockage of which by an antioxidant increases DUSP6 expression,
dephosphorylation of MAPK1/ERK2, and downregulation of cell
proliferation (23).
EFFECTS OF MAPK ACTIVATION
Phosphorylated MAPK1/ERK2 translocates into the nucleus,
phosphorylates various transcription factors, and induces expres-
sion of downstream genes that are thought to play significant roles
in malignant phenotypes of pancreatic cancer (10, 24). To identify
such downstream genes, a comparison of the gene expression pro-
files of pancreatic cancer cells with and without exogenous expres-
sion of DUSP6, which dephosphorylates MAPK, was carried out
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(24). The comparison revealed numerous differentially expressed
genes involved in the cell cycle and mitosis,DNA replication, recep-
tor signaling, and transport. These included AURKA, AURKB,
TPX2, CENPA, EPHA2, CCNB2, IFITM1, RARRES3, SOX4, and
PYCARD (24).
AURKA encodes aurora kinase A, a kinase that phosphory-
lates molecules involved in spindle formation during mitosis (25).
Promoter activity of AURKA is positively associated with MAPK
activity, i.e., active MAPK upregulates the promoter activity and
induces the expression of AURKA (24). The promoter region of
AURKA harbors binding sites for ETS2, a substrate of MAPK (26).
Knockdown of ETS2 induces downregulation of AURKA (24).
These results indicate that active MAPK induces the expression of
AURKA via ETS2. Aurora kinase A is overexpressed in the major-
ity of pancreatic cancers, which is consistent with the observation
that most pancreatic cancers produce constitutively active MAPK.
Knockdown of AURKA in pancreatic cancer cells results in cell
cycle arrest at G2/M and hence, suppression of cellular prolifer-
ation (27). Moreover, the knockdown of AURKA enhances the
effect of chemotherapy with taxane (27).
To identify genes with an important role in cellular prolifer-
ation from among those downstream of MAPK, a knockdown
screen was conducted, testing the effect of RNA interference tar-
geting the downstream genes on in vitro proliferation of pan-
creatic cancer cells (28). The results of this study indicated that
AURKB, CENPA, EBNA1BP2, GOLT1A, KIF11, NEDD4L, SON,
TPX2, and WDR5 play a crucial role in in vitro proliferation,
similarly to AURKA (28). Among them, SON, a gene encoding
SON, which is involved in nuclear speckle organization and RNA
processing, was the most significant target for suppression of pro-
liferation (28). SON is required for efficient RNA processing of
transcripts involved in cell cycle progression (29, 30). Knock-
down of SON in cultured pancreatic cancer cells caused G2/M
arrest and apoptosis (28). By using a subcutaneous xenograft
model in immunocompromised mice, pancreatic cancer cells with
knockdown of SON resulted in a significant reduction in in vivo
tumorigenesis (28). Moreover, SON is overexpressed in ductal
adenocarcinoma of the pancreas, while its expression is lower in
PanIN and normal ductal cells (28). The suppressive effect of SON
knockdown on in vitro proliferation is unremarkable in normal
ductal cells (28). These results indicate that pancreatic cancer cells
may depend on SON to maintain their active proliferation and
tumorigenicity (28). Effectiveness of these targetable downstream
genes for treatment of various cancers has been also reported
recently (31–37).
MicroRNAs are endogenous short non-coding RNAs that inter-
act with protein-coding messenger RNAs and regulate translation
(38, 39). MiRNAs play important roles in physiological develop-
ment as well as in pathological conditions, including cancer (40).
They are aberrantly expressed in many cancers including pan-
creatic cancer. Such aberrant expression is thought to be primarily
associated with an altered copy number of genomic loci coding for
miRNAs. However, signal transduction pathways can also alter the
expression of miRNAs, some of which therefore may be affected
by active MAPKs in pancreatic cancer. The association between
miRNAs and MAPK in pancreatic cancer cells was investigated
by comparing miRNA expression in cells with active or attenuated
MAPK (41). The results indicated that miR-7, miR-34a, miR-193b,
and miR-181d were preferentially associated with MAPK activ-
ity, of which, miR-7 was upregulated, while miR-34a, miR-193b,
and miR-181d were downregulated. MiR-7 is known to target
EGFR, a gene upstream of MAPK. The upregulation of miR-7
by MAPK may induce downregulation of EGFR and subsequent
downregulation of MAPK, thus forming a feedback loop. MiR-
34a is a highly conserved miRNA and is known to be upregulated
by tumor protein 53 (TP53), a tumor suppressor (42, 43). MAPK
downregulates miR-34a, therefore, MAPK is thought to counteract
TP53’s role in controlling the expression of this miRNA, and can
attenuate TP53’s tumor suppressive function. Expression of miR-
193b is lowered in various cancers, and its overexpression induces
suppression of proliferation of cancer cells, including those of
pancreatic cancer. Targets of miR-193b have been shown to be
CCND1, NT5E, PLAU, STARD7, STMN1, and YWHAZ, which are
involved in the cell cycle, conversion of adenosine monophosphate
to adenosine, urokinase-type plasminogen activation, lipid bind-
ing, cell cycle progression, and signal transduction, respectively
(41). Some of these genes are shown to promote proliferation
of pancreatic cancer cells, such that suppression of miR-193b
by MAPK would result in accelerated proliferation. Associations
between MAPK and miRNAs and their relevance for diseases have
been also reported (44–47).
CONCLUSION AND PERSPECTIVES
The combination of KRAS mutation and DUSP6 abrogation plays
a synergistic role in the constitutive activation of MAPK in pan-
creatic cancer. Active MAPK induces a variety of genes, including
miRNAs involved in malignant cancer phenotypes. By blocking the
functions of such induced genes, it is possible to attenuate malig-
nant phenotypes (Figure 2). The development of drugs targeting
genes downstream of MAPK may provide a novel therapeutic
option for pancreatic cancer.
FIGURE 2 | Activation of RAS–MAPK pathway induces expression of
numerous genes, some of which can be targeted. Abbreviations are GAP,
GTPase-activating protein; GEF, guanine nucleotide exchange factor; GF,
growth factor; P, phosphorylation; RTK, receptor tyrosine kinase; and TF,
transcription factor.
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